EUVIMEDEUVIMED entdecken
Crossref

Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia ― A Post-Marketing Survey (J-POSSIBLE) ―

Arihiro Kiyosue, Satoshi Yasuda, Akiyoshi Tomura, Makiko Usami, Hidenori Arai

Circulation Journal · 2023

DOI: 10.1253/circj.cj-22-0445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Journal, 2023. Verfasst von Arihiro Kiyosue und 4 weiteren Autor:innen. Beteiligte Einrichtung: Moriyama Memorial Hospital, Cardiovascular Center. Hauptthemen laut MEDLINE: Hypercholesterolemia, Hyperlipoproteinemia Type II, Hyperlipidemias, Anticholesteremic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study evaluated the safety and effectiveness of alirocumab in Japanese patients with familial hypercholesterolemia (FH) or non-FH in a real-world clinical setting. METHODS AND RESULTS: This post-marketing surveillance study had a 2-year standard observation period. The study included Japanese patients with hypercholesterolemia who were treatment naïve to alirocumab, had a high risk of developing cardiovascular events, and had an insufficient response to, or were unsuitable for, treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Alirocumab was administered at a dose of 75 or 150 mg via subcutaneous injection every 2 or 4 weeks. Overall, 1,177 and 1,038 patients were included in the safety and effectiveness analysis populations, respectively. The incidence of adverse drug reactions (ADRs) was 3.4% (40/1,177). The time to ADR occurrence was within 4 weeks in half the patients experiencing ADRs (n=20). There were no meaningful differences in the ADRs experienced in the FH and non-FH groups. The mean (±SE) percentage changes in low-density lipoprotein cholesterol from baseline to last observation carried forward were -46.9±2.1% and -42.7±2.0% in the non-FH and FH groups, respectively. Total cholesterol, triglycerides, apolipoprotein B/E, and lipoprotein(a) concentrations were decreased at Week 4 and maintained until Week 104 in the overall population. CONCLUSIONS: Alirocumab was well tolerated and showed effectiveness in Japanese patients with hypercholesterolemia in a real-world clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercholesterolemiaHyperlipoproteinemia Type IIHyperlipidemiasAnticholesteremic AgentsHumansProprotein Convertase 9Double-Blind MethodCholesterol, LDLAntiviral AgentsSubtilisinsTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AlirocumabFamilial hypercholesterolemiaLipid-lowering therapyPCSK9 inhibitorPost-marketing survey

Substanzen

Proprotein Convertase 9Cholesterol, LDLAntiviral AgentsSubtilisinsAnticholesteremic AgentsalirocumabAntibodies, Monoclonal, HumanizedPCSK9 protein, human

Autor:innen und Institutionen

  • Moriyama Memorial Hospital, Cardiovascular Center.
  • Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.
  • General Medicines Medical, Sanofi.
  • Post-Authorization Regulatory Studies, Sanofi.
  • National Center for Geriatrics and Gerontology.

Zitieren

APA

Kiyosue, A., Yasuda, S., Tomura, A., Usami, M., & Arai, H. (2023). Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia ― A Post-Marketing Survey (J-POSSIBLE) ―. Circulation Journal. https://doi.org/10.1253/circj.cj-22-0445

Vancouver

Kiyosue A, Yasuda S, Tomura A, Usami M, Arai H. Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia ― A Post-Marketing Survey (J-POSSIBLE) ―. Circulation Journal. 2023. doi:10.1253/circj.cj-22-0445

BibTeX
@article{Kiyosue2023,
  author = {Kiyosue, Arihiro and Yasuda, Satoshi and Tomura, Akiyoshi and Usami, Makiko and Arai, Hidenori},
  title = {Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia ― A Post-Marketing Survey (J-POSSIBLE) ―},
  journal = {Circulation Journal},
  year = {2023},
  doi = {10.1253/circj.cj-22-0445}
}
Kostenlos starten →